Evidence map›Paper›PMID 32907988›Full record

ArticleJournal of lipid research2020

High resolution structure of human apolipoprotein (a) kringle IV type 2: beyond the lysine binding site.

Alice Santonastaso, Maristella Maggi, Hugo De Jonge, Claudia Scotti

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Zerlasiran for Lipoprotein(a) Reduction: Mechanisms, Evidence, and Future Directions.Cardiovascular & hematological disorders drug targets · 2026
    Review
  3. Review
  4. Lipoprotein(a) and cardiovascular disease.The Biochemical journal · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1).Acta crystallographica. Section F, Structural biology communications · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alice SantonastasoDepartment of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, Italy.
Maristella MaggiDepartment of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, Italy.
Hugo De JongeDepartment of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, Italy.
Claudia ScottiDepartment of Molecular Medicine, Unit of Immunology and General Pathology, University of Pavia, Pavia, Italy. Electronic address: claudia.scotti@unipv.it.
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein (a) [Lp(a)] is characterized by an LDL-like composition in terms of lipids and apoB100, and by one copy of a unique glycoprotein, apo(a). The apo(a) structure is mainly based on the repetition of tandem kringle domains with high homology to plasminogen kringles 4 and 5. Among them, kringle IV type 2 (KIV-2) is present in a highly variable number of genetically encoded repeats, whose length is inversely related to Lp(a) plasma concentration and cardiovascular risk. Despite it being the major component of apo(a), the actual function of KIV-2 is still unclear. Here, we describe the first high-resolution crystallographic structure of this domain. It shows a general fold very similar to other KIV domains with high and intermediate affinity for the lysine analog, ε-aminocaproic acid. Interestingly, KIV-2 presents a lysine binding site (LBS) with a unique shape and charge distribution. KIV-2 affinity for predicted small molecule binders was found to be negligible in surface plasmon resonance experiments; and with the LBS being nonfunctional, we propose to rename it "pseudo-LBS". Further investigation of the protein by computational small-molecule docking allowed us to identify a possible heparin-binding site away from the LBS, which was confirmed by specific reverse charge mutations abolishing heparin binding. This study opens new possibilities to define the pathogenesis of Lp(a)-related diseases and to facilitate the design of specific therapeutic drugs.

Indexed as

KringlesLysineApolipoproteins ABinding SitesCrystallography, X-RayHumansModels, MolecularProtein BindingApolipoproteins ALysineapolipoproteinsdiseases/atherosclerosislipoprotein (a)low density lipoproteinX-ray crystallographyε-aminocaproic acid

Identifiers

PMID32907988
PMCPMC7707183
OpenAlexW3084395183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.